Vipivotide tetraxetan Ligand-Linker Conjugate

Cat. No.: HY-43869

CAS No.: 1703768-74-4

Molecular Formula: $C_{33}H_{45}N_5O_9$

Molecular Weight: 655.74

Target: ADC Linker

Pathway: Antibody-drug Conjugate/ADC Related

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (190.62 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.5250 mL	7.6250 mL	15.2499 mL
	5 mM	0.3050 mL	1.5250 mL	3.0500 mL
	10 mM	0.1525 mL	0.7625 mL	1.5250 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (3.17 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (3.17 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (3.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA)[1].

IC_{50} & Target

Non-cleavable Linker

In Vitro

Vipivotide tetraxetan Ligand-Linker Conjugate

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA